Synergy Pharmaceuticals — Technical Presentation (October 2010)
20 slides from Synergy Pharmaceuticals's technical presentation, Oct 18, 2010
Slide 1: Phase IIa Study of Plecanatide (SP-304) in Chronic Idiopathic Constipation
A Phase IIa Randomized, Double-Blind, Placebo-Controlled, 14-Day Repeat, Oral, Dose-Ranging Study to Assess the Safety, Pharmacokinetic and Pharmacodynamic Effects of Plecanatide (SP-304) in Patients with Chronic Idiopathic Constipation (Protocol No. SP-SP304201-09) K. Shailubhai, C. Talluto,S. Comi
Slide 2: Background
Background Uroguanylin (UG) and guanylin (GN) are physiological agonists of guanylate cyclase-C (GC-C) receptor. Activation of the GC-C receptor stimulates intracellular synthesis of cyclic GMP, resulting in activation of the cystic fibrosis transmembrane conductance regulator (CFTR). Activation of
Slide 3: Known mammalian agonists of GC-C
Fig. 1: Known mammalian agonists GC-C N S S N Y C C E L C C N P A C T G C Y E. Coli ST Q E E C E L C I N M A C T G Y Lymphoguanylin Guanylin S H T C E I C A F A A C A G C N D D C E L C V N V A C T G C L Uroguanylin A B Uroguanylin and E. coli enterotoxin ST peptide bind to the same GC-C receptors an
Slide 4: GC-C signaling in the intestine
Cross section of intestine GC-C signaling in the intestine Binding of GC-C agonists to their receptors located in the GI lumen stimulates fluid, chloride and bicarbonate secretions. Optimal volume of fluid secretion in the proximal intestine is essential for normal bowel movement. Reduced volume of
Slide 5: Plecanatide is a superior analog of the natural GI hormone uroguanylin
Uroguanylin Plecanatide Fig.3: Plecanatide is a superior analog of the natural GI hormone uroguanylin N D D C E L C V N V A C T G C L N D E C E L C V N V A C T G C L
Slide 6: Objectives
Objectives Primary Objective: To evaluate the safety of plecanatide for 14 days in patients with CC Secondary Objectives: To assess the pharmacokinetic profile after the first daily dose of plecanatide and prior to and after the last dose of plecanatide To assess the time to first bowel movement aft
Slide 7: Methods
Methods This was a Phase IIa, randomized, double-blind, placebo-controlled, 14-day repeat, oral, dose-ranging study There were four dose cohorts in this trial: Plecanatide (0.3 mg, 1.0 mg, 3.0 mg or 9.0 mg) and matching placebo. 3:1 randomization (plecanatide:matching placebo) 20 subjects per dose c
Slide 8: Primary Subject Selection Criteria
Primary Subject Selection Criteria: Meet modified ROME III criteria for CC Colonoscopy within past 5 years with no significant finding Good health as determined by physical examination, medical history, vital signs, ECG, clinical chemistry, hematology, urinalysis, drug screen and serology assessment
Slide 9: Statistical Analysis
Statistical Analysis Primary endpoints for the safety evaluation were summarized by descriptive statistics for the patients that received at least one dose of plecanatide or placebo (safety population) The secondary assessments for pharmacodynamic activity were summarized by descriptive statistics f
Slide 10: Results - Demographics
Results - Demographics Placebo 0.3 mg 1.0 mg 3.0 mg 9.0 mg Age * 47.7 (14.6) 51.1 (11.9) 50.5 (10.6) 48.5 (16.1) 47.3 (12.7) Gender Female 18 (90%) 12 (85.7%) 14 (100%) 13 (86.7%) 12 (80%) Male 2 (10%) 2 (14.3%) 0 (0%) 2 (13.3%) 3 (20%) Race Caucasian 17 (85%) 13 (92.9%) 12 (85.7%) 14 (93.3%) 12 (80
Slide 11: Results - Safety
No detectable systemic absorption of plecanatide (assay sensitivity > 10 ng/mL) No serious adverse events (SAE) reported in subjects receiving plecanatide No deaths reported in this study % subjects who reported AEs considered related to treatment Placebo 10% (2/20) Plecanatide 17.2% (10/58) % subje
Slide 12: GI-Related Adverse Event Summary with Relationship to Treatment
Table 2: GI-Related Adverse Event Summary with Relationship to Treatment AE Placebo n=20 0.3 mg n=14 1.0 mg n=14 3.0 mg n=15 9.0 mg n=15 Ab Cramping 1 (5.0%) 0 0 0 0 Ab Pain 1 (5.0%) 0 0 0 0 Bloating 0 0 0 0 1 (6.7%) Diarrhea 1 (5.0%) 0 0 0 0 Flatulence 2 (10.0%) 0 0 0 0 Nausea 0 1 (7.1%) 0 0 1 (6.7
Slide 13: Results - Efficacy: Plecanatide reduces the time to first bowel movement
Figure 4: Plecanatide reduces the time to first bowel movement Median reduction in time to first BM (hours) n= 16 n= 12 n=14 n= 13 n=15 n=54 Results - Efficacy Median time to first BM (hours) 0 5 10 15 20 25 placebo 0.3 mg 1.0 mg 3.0 mg 9.0 mg all
Slide 14: Change from Baseline in Complete Spontaneous Bowel Movements
Figure 6: Change from Baseline in Complete Spontaneous Bowel Movements (CSBM) after 14-Days of Treatment (Per Protocol Population) 0.0 1.0 2.0 3.0 4.0 5.0 Placebo 0.3mg 1.0mg 3.0mg 9.0mg Overall Tx Plecanatide Dose (mg) Average Number of CSBM/wk Pre-Treatment 14-Day Treatment
Slide 15: Change from Baseline in Bristol Stool Form Score
Figure 7: Change from Baseline in Bristol Stool Form Score (BSFS) after 14-Days of Treatment (Per Protocol Population) 0.0 1.0 2.0 3.0 4.0 5.0 Placebo 0.3mg 1.0mg 3.0mg 9.0mg Overall Tx Plecanatide Dose (mg) Average Weekly BSFS Pre-Treatment 14-Day Treatment
Slide 16: Change from Baseline in Straining Scores
Figure 8: Change from Baseline in Straining Scores after 14-Days of Treatment (Per Protocol Population) 0.0 1.0 2.0 3.0 4.0 5.0 Placebo 0.3 mg 1.0 mg 3.0 mg 9.0 mg Overall Tx Plecanatide Dose (mg) Average Weekly Straining Score Pre-Treatment 14-Day Treatment
Slide 17: Improvements in Abdominal Discomfort Scores
Figure 9: Percent of Subjects Reporting Improvements in Abdominal Discomfort Scores after 14-Days of Treatment (Per Protocol Population) 0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 80.0 Placebo 0.3 mg 1.0 mg 3.0 mg 9.0 mg Overall Tx Treatment Groups % of Subjects Reporting Improvement in Abdominal Discom
Slide 18: Patient Global Assessment Questionnaire: Constipation Severity
Patient Global Assessment Questionnaire Constipation Severity 0 20 40 60 80 Placebo 0.3 1.0 3.0 9.0 Overall Tx Plecanatide Dose (mg) % of Subjects Reporting Improvement in Constipation Severity Pre-Treatment 14-Day Treatment
Slide 19: Patient Global Assessment Questionnaire: Overall Relief
Patient Global Assessment Questionnaire Overall Relief % of Subjects Reporting Overall Relief 0 20 40 60 80 100 Pre-Treatment 14-Day Treatment Placebo 0.3 1.0 3.0 9.0 Overall Tx Plecanatide Dose (mg)
Slide 20: Conclusions
Conclusions There was no detectable systemic absorption of plecanatide at any dose up to 9 mg (assay sensitivity: 10 ng/mL) The safety profile demonstrated minimal adverse events No SAEs reported in subjects receiving plecanatide No reports of diarrhea in subjects who received plecanatide All plecan
Synergy Pharmaceuticals — Technical Presentation (October 2010) on 6ix